Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 17

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 17
---
 to further develop the emerging market for MRD testing for both clinical and biopharmaceutical use cases.

9

•Expand patient use cases by continuing to generate clinical evidence in clonoSEQ utility throughout the patient continuum of care. clonoSEQ MRD testing has the potential to inform patient management and support drug development in a wide range of contexts and at multiple time points, both for newly diagnosed and relapsed/refractory patients and both during and after treatment. In addition to expanding the indications for which clonoSEQ has shown clinical utility, our evidence generation strategy also addresses the goal of expanding patient use cases within existing promoted indications. Our strategy for expanding use cases is informed by provider and biopharmaceutical feedback on current unmet needs as well as by the evolving treatment landscape. For example, in multiple myeloma, patients have traditionally been prescribed indefinite maintenance therapy; however, in recent years novel treatment regimens are enabling newly diagnosed patients to achieve deeper and more sustained responses, which has increased provider interest in offering patients time off therapy. To address this emerging trend, Adaptive and its collaborators have generated and will continue to generate data demonstrating the role of clonoSEQ to determine which patients can safely discontinue treatment and to monitor patients in treatment-free remission.  

•Enhance customer experience with EMR integrations. In October 2022, we entered into a partnership with Epic to integrate clonoSEQ into Epic’s EMR system, which we believe will enable easier test ordering and results access for the clonoSEQ test. As of December 2024, clonoSEQ is integrated into the Epic instances at 18 customer accounts. In 2024, we entered into a partnership with Flatiron Health, Inc. (“Flatiron”), a leading provider of electronic health records (“EHR”) software and services for community oncology, to integrate clonoSEQ into Flatiron’s OncoEMR™ system. Through 2025 we expect to integrate more Epic accounts and launch the integration with Flatiron in the community to drive further clonoSEQ adoption.

In addition to these strategies, in January 2025, we entered into a multi-year exclusive strategic commercial collaboration with NeoGenomics, Inc. (“NeoGenomics”) that will integrate clonoSEQ with NeoGenomics’ COMPASS® and CHART® offerings in complex blood cancers. We have begun to collaborate with NeoGenomics to implement the commercial and operational infrastructure to support our partnership and expect to launch cross-promotional efforts later in 2025.

The strategies described above are